Publications by authors named "Eiftu S Haile"
Objectives: To assess whether the effect of sarcopenia on neoadjuvant chemotherapy (NAC) toxicity is modified by borderline renal function (estimated glomerular filtration rate [eGFR] 40-65 mL/min) and whether sarcopenia and borderline renal function are independently associated with NAC toxicity risk.
Patients And Methods: All patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) between 2010 and 2022, with available cross-sectional imaging prior to NAC initiation, were included. Skeletal mass was measured from axial computed tomography images obtained at the level of the L3 vertebral body, using Aquarius Intuition software.
Medical management of benign prostatic hyperplasia (BPH) has progressed gradually in recent years and remains the starting point for most symptomatic patients seeking treatment. Beyond well-known alpha-blockers and 5-alpha reductase inhibitors, there is growing evidence for the use of phosphodiesterase-5 inhibitors and beta-3 agonists in managing the condition, which may afford additional relief of "bothersome" symptoms in some patients. This review details contemporary medical management of BPH with an emphasis on the indications for certain classes of pharmacotherapy and their relative benefits and side effects.
View Article and Find Full Text PDFArticle Synopsis
- Climacturia is a common but often overlooked issue that arises as a complication from prostate cancer treatments such as radical prostatectomy (RP) and radiation therapy (RT).
- A study analyzed data from 1,117 patients to assess the prevalence of climacturia and its impact on patients and their partners, finding that 39% of those with RP alone reported this issue, compared to 14% with RT alone, and 52% with both treatments.
- Key predictors for climacturia included having a history of RP or RT, prior prostate surgeries, and erectile dysfunction, with significant patient/partner dissatisfaction noted among those affected.